Full Press Release Details
Quarterly report for entities
subject to Listing Rule 4.7B
Quarterly report for entities
subject to Listing Rule 4.7B
Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16
| Name of entity | ||||||||||||
| Prima BioMed Limited | ||||||||||||
| ABN | Quarter ended ( current quarter ) | |||||||||||
| 90 009 237 889 | 30 th September 2017 |
| Consolidated statement of cash flows | Current quarter $A 000 | Year to date (3 months) $A 000 | ||||||||||||||||||||||||
| 1. | Cash flows from operating activities | |||||||||||||||||||||||||
| 1.1 | Receipts from customers | 1,279 | 1,279 | |||||||||||||||||||||||
| 1.2 | Payments for | |||||||||||||||||||||||||
| (a) | research and development | (2,046) | (2,046) | |||||||||||||||||||||||
| (b) | product manufacturing and operating costs | - | - | |||||||||||||||||||||||
| - | (c) | advertising and marketing | (46) | (46) | ||||||||||||||||||||||
| (d) | leased assets | - | - | |||||||||||||||||||||||
| (e) | staff costs | (870) | (870) | |||||||||||||||||||||||
| (f) | administration and corporate costs | (376) | (376) | |||||||||||||||||||||||
| 1.3 | Dividends received (see note 3) | - | - | |||||||||||||||||||||||
| 1.4 | Interest received | 16 | 16 | |||||||||||||||||||||||
| 1.5 | Interest and other costs of finance paid | - | - | |||||||||||||||||||||||
| 1.6 | Income taxes paid | - | - | |||||||||||||||||||||||
| 1.7 | Government grants and tax incentives | 1,317 | 1,317 | |||||||||||||||||||||||
| 1.8 | Other (provide details if material) | - | - | |||||||||||||||||||||||
| 1.9 | Net cash from / (used in) operating activities | (726) | (726) | |||||||||||||||||||||||
| 2. | Cash flows from investing activities | |||||||||||||||||||||||||
| 2.1 | Payments to acquire: | |||||||||||||||||||||||||
| (a) | property, plant and equipment | (1) | (1) | |||||||||||||||||||||||
| (b) | businesses (see item 10) | - | - | |||||||||||||||||||||||
| (c) | investments | - | - |
Quarterly report for entities subject to Listing Rule 4.7B
| Consolidated statement of cash flows | Current quarter $A 000 | Year to date (3 months) $A 000 | ||||||||||||||||||||||
| (d) | intellectual property | - | - | |||||||||||||||||||||
| (e) | other non-current assets | - | - | |||||||||||||||||||||
| 2.2 | Proceeds from disposal of: | |||||||||||||||||||||||
| (a) | property, plant and equipment | - | - | |||||||||||||||||||||
| (b) | businesses (see item 10) | - | - | |||||||||||||||||||||
| (c) | investments | - | - | |||||||||||||||||||||
| (d) | intellectual property | - | - | |||||||||||||||||||||
| (e) | other non-current assets | - | - | |||||||||||||||||||||
| 2.3 | Cash flows from loans to other entities | - | - | |||||||||||||||||||||
| 2.4 | Dividends received (see note 3) | - | - | |||||||||||||||||||||
| 2.5 | Other (provide details if material) | - | - | |||||||||||||||||||||
| 2.6 | Net cash from / (used in) investing activities | (1) | (1) | |||||||||||||||||||||
| 3. | Cash flows from financing activities | |||||||||||||||||||||||
| 3.1 | Proceeds from issues of shares | 6,562 | 6,562 | |||||||||||||||||||||
| 3.2 | Proceeds from issue of convertible notes | - | - | |||||||||||||||||||||
| 3.3 | Proceeds from exercise of share options | - | - | |||||||||||||||||||||
| 3.4 | Transaction costs related to issues of shares, convertible notes or options | (1,069) | (1,069) | |||||||||||||||||||||
| 3.5 | Proceeds from borrowings | - | - | |||||||||||||||||||||
| 3.6 | Repayment of borrowings | - | - | |||||||||||||||||||||
| 3.7 | Transaction costs related to loans and borrowings | - | - | |||||||||||||||||||||
| 3.8 | Dividends paid | - | - | |||||||||||||||||||||
| 3.9 | Other (provide details if material) | - | - | |||||||||||||||||||||
| 3.10 | Net cash from / (used in) financing activities | 5,493 | 5,493 | |||||||||||||||||||||
| 4. | Net increase / (decrease) in cash and cash equivalents for the period | |||||||||||||||||||||||
| 4.1 | Cash and cash equivalents at beginning of quarter/year to date | 12,295 | 12,295 | |||||||||||||||||||||
| 4.2 | Net cash from / (used in) operating activities (item 1.9 above) | (726) | (726) | |||||||||||||||||||||
| 4.3 | Net cash from / (used in) investing activities (item 2.6 above) | (1) | (1) | |||||||||||||||||||||
| 4.4 | Net cash from / (used in) financing activities (item 3.10 above) | 5,493 | 5,493 |
Quarterly report for entities subject to Listing Rule 4.7B
| Consolidated statement of cash flows | Current quarter $A 000 | Year to date (3 months) $A 000 | ||||||||||||||||||
| 4.5 | Effect of movement in exchange rates on cash held | (107) | (107) | |||||||||||||||||
| 4.6 | Cash and cash equivalents at end of quarter | 16,954 | 16,954 | |||||||||||||||||
| 5. | Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | Current quarter $A 000 | Previous quarter $A 000 | |||||||||||||||||
| 5.1 | Bank balances | 14,388 | 8,395 | |||||||||||||||||
| 5.2 | Call deposits | 2,300 | 3,636 | |||||||||||||||||
| 5.3 | Bank overdrafts | - | - | |||||||||||||||||
| 5.4 | Other (provide details) | 266 | 264 | |||||||||||||||||
| 5.5 | Cash and cash equivalents at end of quarter (should equal item 4.6 above) | 16,954 | 12,295 | |||||||||||||||||
| 6. | Payments to directors of the entity and their associates | Current quarter $A 000 | ||||||||||||||||||
| 6.1 | Aggregate amount of payments to these parties included in item 1.2 | 257 | ||||||||||||||||||
| 6.2 | Aggregate amount of cash flow from loans to these parties included in item 2.3 | - | ||||||||||||||||||
| 6.3 | Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2 | |||||||||||||||||||
| Directors fees and consulting fees at normal commercial rates | ||||||||||||||||||||
| 7. | Payments to related entities of the entity and their associates | Current quarter $A 000 | ||||||||||||||||||
| 7.1 | Aggregate amount of payments to these parties included in item 1.2 | - | ||||||||||||||||||
| 7.2 | Aggregate amount of cash flow from loans to these parties included in item 2.3 | - | ||||||||||||||||||
| 7.3 | Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2 |
Quarterly report for entities subject to Listing Rule 4.7B
| 8. | Financing facilities available Add notes as necessary for an understanding of the position | Total facility amount at quarter end $A 000 | Amount drawn at quarter end $A 000 | |||||||||||||||||
| 8.1 | Loan facilities | - | - | |||||||||||||||||
| 8.2 | Credit standby arrangements | - | - | |||||||||||||||||
| 8.3 | Other (please specify) | - | - | |||||||||||||||||
| 8.4 | Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well. | |||||||||||||||||||
| 9. | Estimated cash outflows for next quarter | $A 000 | ||||||||||||||||||
| 9.1 | Research and development | 2,451 | ||||||||||||||||||
| 9.2 | Product manufacturing and operating costs | - | ||||||||||||||||||
| 9.3 | Advertising and marketing | 75 | ||||||||||||||||||
| 9.4 | Leased assets | - | ||||||||||||||||||
| 9.5 | Staff costs | 798 | ||||||||||||||||||
| 9.6 | Administration and corporate costs | 947 | ||||||||||||||||||
| 9.7 | Other (provide details if material) | - | ||||||||||||||||||
| 9.8 | Total estimated cash outflows | 4,271 | ||||||||||||||||||
| 10. | Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above) | Acquisitions | Disposals | |||||||||||||||||
| 10.1 | Name of entity | - | - | |||||||||||||||||
| 10.2 | Place of incorporation or registration | - | - | |||||||||||||||||
| 10.3 | Consideration for acquisition or disposal | - | - | |||||||||||||||||
| 10.4 | Total net assets | - | - | |||||||||||||||||
| 10.5 | Nature of business | - | - |
Quarterly report for entities subject to Listing Rule 4.7B
Compliance statement
| Sign here: | ||||||||||||||
| Company Secretary | Date: 11 October 2017 | |||||||||||||
| Print name: | Deanne Miller |